OP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDY (2024)

OP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDY (1)

  • Subscribe
  • Log In More

    Log in via Institution

    Log in via OpenAthens

    Log in using your username and password

  • Basket
  • Search More

    Advanced search

  • Latest content
  • Current issue
  • Archive
  • Authors
  • About
  • Podcasts

Advanced search

  • CloseMore

    Main menu

    • Latest content
    • Current issue
    • Archive
    • Authors
    • About
    • Podcasts
  • Subscribe
  • Log in More

    Log in via Institution

    Log in via OpenAthens

    Log in using your username and password

  • BMJ Journals

You are here

  • Home
  • Archive
  • Volume 83,Issue Suppl 1
  • OP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDY

Email alerts

Article Text

Article menu

  • Article Text
  • Article info
  • Citation Tools
  • Share
  • Rapid Responses
  • Article metrics
  • Alerts

PDF

Scientific Abstracts

Oral Abstract Presentations

Clinical Abstract Sessions: Rheumatoid arthritis - A focus on pain and prognosis

OP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDY

  1. G. Frazzei1,2,
  2. S. Cramer1,
  3. R. Landewé1,2,
  4. K. Maijer3,
  5. D. Gerlag1,
  6. P. P. Tak4,
  7. N. De Vries1,2,
  8. L. G. M. Van Baarsen1,2,
  9. R. F. Van Vollenhoven1,2,
  10. S. W. Tas1,2
  1. 1Amsterdam University Medical Center, University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam, Netherlands
  2. 2Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
  3. 3Tergooi Hospital, Department of Dermatology, Hilversum, Netherlands
  4. 4Candel Therapeutics, Needham, United States of America

Abstract

Background: Over the past 10 years, several trials have investigated prevention of rheumatoid arthritis (RA) by biological disease modifying antirheumatic drug (DMARD) therapies. Early treatment in RA-risk individuals in the preclinical phase – i.e. before the disease has been fully established – has the potential to prevent disease or delay its onset, which may have a positive impact on both patient and society. The PRAIRI study was a randomized, double-blind, controlled trial in which seropositive arthralgia patients received a single dose of rituximab (RTX) or placebo (PBO). This resulted in a significant delay of arthritis development of up to 12 months [1]. Secondary outcomes were the effects of RTX treatment on quality of life as measured by various patient reported outcomes (PROs).

Objectives: To evaluate the impact of RTX treatment on the quality of life of RA-risk individuals in the PRAIRI study as measured by various patient reported outcomes (PROs).

Methods: Eighty-one RA-risk individuals were included in the PRAIRI study between 2010 and 2013, and treated with one single dose of either PBO or 1000 mg RTX; all study subjects also received standard co-medication, consisting of 100 mg methylprednisolone and anti-histamines. Data on quality of life were collected at baseline and 1, 4, 6, 12, and 24 months using the following PRO-questionnaires: visual analogue scale (VAS) pain, health assessment questionnaire (HAQ) score, EuroQol five dimension (EQ-5D), and both physical component score (PCS) and mental component score (MCS) of the 36-item short form heath survey (SF-36). Changes in quality of life over time and potential impact on perceived arthritis severity at onset of clinically overt disease were analyzed for both treatment groups.

Results: PRO data were available for 78 patients. No convincing effect on VAS pain, HAQ score, EQ-5D, or PCS and MCS of SF-36 was found in either RTX or PBO groups. Compared to the PBO group, the RTX group had slightly worse baseline scores for VAS pain (mean ± SEM: PBO = 23.11 ± 3.68; RTX = 30.88 ± 3.41) and HAQ score (PBO = 0.26 ± 0.06; RTX = 0.56 ± 0.09). However, baseline PRO scores were similar to the general “healthy” population and remained stable during the two-year follow up period for both RTX and PBO group (Figure 1A). At the time of arthritis development, we also did not observe a significant difference in VAS pain (mean ± SEM: PBO = 51.29 ± 5.99; RTX = 55.83 ± 6.76), HAQ score (PBO = 0.86 ± 0.20; RTX = 0.93 ± 0.15), EQ-5D (PBO = 0.64 ± 0.05; RTX = 0.63 ± 0.06), PCS (PBO = 39.63; ± 3.08; RTX = 41.13 ± 2.54) or MCS (PBO = 50.91 ± 1.83; RTX = 48.31 ± 3.93) of the SF-36 questionnaire (Figure 1B) compared to baseline.

Conclusion: A single dose of RTX in RA-risk individuals delayed the onset of arthritis by a year, but did not have a positive impact on quality of life as measured by various PROs. In RA-risk individuals developing arthritis, RTX also did not significantly alter PROs and/or perceived disease severity at the time of arthritis development. Since RTX did not have a negative effect on quality of life either, these data underscore that RTX treatment is well-tolerated in the preclinical phase of RA but additional research is required to determine whether RTX based strategies can prevent RA.

REFERENCES: [1] Gerlag DM et al., “Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study”, Ann Rheum Dis. 2019 Feb;78(2):179-185.

  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1.

PRO scores for VAS pain, HAQ, EQ-5D, PCS, and MCS of SF-36 questionnaire, stratified for treatment (PBO=orange line; RTX=blue line), reported as mean and SEM. On the left, PRO scores are shown for a two-year period (n at baseline: PBO= 37; RTX= 41) (A). On the right, PRO scores (n PBO= 14; n RTX=12)at baseline and arthritis visit are shown for patients that developed RA within study time (B). Median (IQR) time of RA onset was 12 (2-15) months in PBO group and 16.5 (9.75-28) in RTX group.

Acknowledgements: NIL.

Disclosure of Interests: Giulia Frazzei: None declared, Sophie Cramer: None declared, Robert Landewé: None declared, Karen Maijer: None declared, Danielle Gerlag: None declared, Paul Peter Tak: None declared, Niek de Vries: None declared, Lisa G.M. van Baarsen: None declared, Ronald F. van Vollenhoven Consultancy and/or speaker: AbbVie, AstraZeneca, Biogen, BMS, Galapagos, GSK, Janssen, Pfizer, RemeGen, UCB, Support for Research or Educational programs (institutional grants): AstraZeneca, BMS, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Sander W. Tas: None declared.

  • Patient Reported Outcome Measures
  • Randomized controlled trial
  • Clinical Trial

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    • Patient Reported Outcome Measures
    • Randomized controlled trial
    • Clinical Trial

    Read the full text or download the PDF:

    Subscribe

    Log in via Institution

    Log in via OpenAthens

    Log in using your username and password

    Read the full text or download the PDF:

    Subscribe

    Log in via Institution

    Log in via OpenAthens

    Log in using your username and password

    OP0053 THE EFFECTS OF RITUXIMAB ON QUALITY OF LIFE, PAIN AND MOBILITY SCORES IN THE PRECLINICAL PHASE OF RHEUMATOID ARTHRITIS: 2 YEAR DATA FROM THE PRAIRI STUDY (2024)

    FAQs

    What is the success rate of rituximab for rheumatoid arthritis? ›

    In the REFLEX Trial, Rituxan plus MTX was proven to slow joint damage for many patients (60%) during the first year of treatment compared to placebo plus MTX (46%).

    What is the best pain relief for rheumatoid arthritis? ›

    In addition to, or instead of, painkillers such as paracetamol, your doctor may prescribe a non-steroidal anti-inflammatory drug (NSAID). This may be a traditional NSAID, such as ibuprofen, naproxen or diclofenac. Or your doctor may prescribe a type called a COX-2 inhibitor, such as celecoxib or etoricoxib.

    What does rituximab do for rheumatoid arthritis? ›

    Rituximab works by lowering the number of these B-cells, to reduce inflammation, pain, swelling and joint damage. If rituximab works for you, you'll probably notice an improvement in your symptoms 8-16 weeks after you start treatment.

    How to slow down rheumatoid arthritis? ›

    Doctors often prescribe a corticosteroid to relieve symptoms quickly, with the goal of gradually tapering off the medication. Conventional DMARDs . These drugs can slow the progression of rheumatoid arthritis and save the joints and other tissues from permanent damage.

    What is the survival rate for rituximab patients? ›

    Three-year event-free survival rates (79% vs. 59%; P < 0.0001) and overall survival rates (93% vs. 84%; P = 0.00001) were both significantly higher for patients treated with the addition of rituximab. There were no additional major adverse effects.

    Why is rituximab so expensive? ›

    Biologic drugs can be expensive because of the research and testing needed to ensure their safety and effectiveness. The drugmaker of a biologic drug can sell it for up to 12 years .

    What can you do for unbearable rheumatoid arthritis pain? ›

    Apply ice or heat for pain, and talk to a doctor about taking NSAIDs. How a specialist can help: They can recommend specific exercises and/or physical therapy, and provide assistive devices like canes. They also prescribe oral and topical medications, as well as injections, starting with cortisone shots.

    What is the most successful drug for rheumatoid arthritis? ›

    For most people, methotrexate is the first-choice treatment for rheumatoid arthritis, according to the American College of Rheumatology. That's because it's affordable, effective for many, and safe.

    What to avoid while on rituximab? ›

    Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis). Rituximab can make you more likely to get infections or may make current infections worse. Stay away from anyone who has an infection that may easily spread (such as chickenpox, COVID-19, measles, flu).

    Is rituximab hard on the body? ›

    Rituxan can cause serious side effects, including: Tumor Lysis Syndrome (TLS): TLS is caused by the fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment or an abnormal heart rhythm. TLS can happen within 12-24 hours after an infusion of Rituxan.

    How long does rituximab take to work for RA? ›

    How long will rituximab take to work? The response to rituximab is often evident only after about six weeks. The duration of your rituximab treatment will depend on your response and will be determined by your consultant.

    What foods flare up rheumatoid arthritis? ›

    High in salt, sugar, and unhealthy fats, processed foods can cause inflammation, weight gain, and heart problems. Not only are they bad for RA, but they're also bad for your overall health. These contain high levels of saturated fat, which can increase inflammation and have negative effects on heart health.

    What is end stage rheumatoid arthritis? ›

    End-stage rheumatoid arthritis (RA) is an advanced stage of disease in which there is severe joint damage and destruction in the absence of ongoing inflammation.

    What is better than rituximab? ›

    Obinutuzumab was developed to potentiate activity and overcome resistance. Pre-clinical data suggests obinutuzumab is superior to rituximab at effecting B cell depletion; however recent phase III clinical trial results have been mixed.

    What is the remission rate for rituximab patients? ›

    They reported that 95% of patients achieved a complete remission at some point, with about 27% of patients achieving long term complete remission off therapy and relapses observed in two-thirds of the patients, as late as 156 months after a successful rituximab cycle (15).

    Is rituximab a high risk medication? ›

    This medicine may cause a rare and serious brain infection called progressive multifocal leukoencephalopathy (PML). The risk for getting this infection is higher if you have rheumatoid arthritis. Talk to your doctor about the benefits of receiving this medicine and the risk for this infection.

    References

    Top Articles
    Latest Posts
    Article information

    Author: Kelle Weber

    Last Updated:

    Views: 5331

    Rating: 4.2 / 5 (53 voted)

    Reviews: 84% of readers found this page helpful

    Author information

    Name: Kelle Weber

    Birthday: 2000-08-05

    Address: 6796 Juan Square, Markfort, MN 58988

    Phone: +8215934114615

    Job: Hospitality Director

    Hobby: tabletop games, Foreign language learning, Leather crafting, Horseback riding, Swimming, Knapping, Handball

    Introduction: My name is Kelle Weber, I am a magnificent, enchanting, fair, joyous, light, determined, joyous person who loves writing and wants to share my knowledge and understanding with you.